Glassia approved for treating alpha 1 antitrypsin deficiency - ONA
Links shared publicly online about this topic.
- 1,042total visits
Glassia approved for treating alpha 1 antitrypsin deficiency - ONA
View full resource at oncologynurseadvisor.com
Tags: COPD, FDA, Emphysema, Glassia
Most Recently Shared on July 6, 2010 at 3:53 pm By:
Glassia approved for treating alpha 1 antitrypsin deficiency http://goo.gl/fb/xUQkp
Kamada Wins FDA Approval for Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency
drugs.com — “Glassia (alpha1-proteinase inhibitor (human)) is used to treat Alpha 1 deficiency. Includes Glassia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 7, 2010 at 9:27 am By:
FDA Approves Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency - http://bit.ly/bpOUdG
Glassia approved for treating alpha 1 antitrypsin deficiency - MPR
empr.com — “Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).” View full resource at empr.com
Most Recently Shared on July 6, 2010 at 3:33 pm By:
MPR News: Glassia approved for treating alpha 1 antitrypsin deficiency: Kamada announced that the FDA has approved... http://bit.ly/bedZ9o
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency
news-medical.net — “Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled t” View full resource at news-medical.net
Most Recently Shared on February 6, 2010 at 4:52 am By:
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficienc... http://bit.ly/9T7yWx
Advertisement
